{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:50:30Z","timestamp":1788576630566,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01-DA039167"],"award-info":[{"award-number":["R01-DA039167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31-DA048586"],"award-info":[{"award-number":["F31-DA048586"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00213-024-06690-x","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:24:50Z","timestamp":1727468690000},"page":"2453-2469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the reinforcing, antinociceptive, and respiratory depressant effects of prototypical and G-protein biased mu-opioid receptor agonists in male and female Sprague\u2013Dawley rats"],"prefix":"10.1007","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6426-8984","authenticated-orcid":false,"given":"C. Austin","family":"Zamarripa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-0811","authenticated-orcid":false,"given":"Tanya","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loc M.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley M.","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Vallender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Sufka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"6690_CR1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1177\/0269881116689257","volume":"31","author":"AA Altarifi","year":"2017","unstructured":"Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS (2017) Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol 31:730\u2013739. https:\/\/doi.org\/10.1177\/0269881116689257","journal-title":"J Psychopharmacol"},{"key":"6690_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbr.2018.01.031","volume":"343","author":"A Armendariz","year":"2018","unstructured":"Armendariz A, Nazarian A (2018) Morphine antinociception on thermal sensitivity and place conditioning in male and female rats treated with intraplantar complete freund\u2019s adjuvant. Behav Brain Res 343:21\u201327. https:\/\/doi.org\/10.1016\/j.bbr.2018.01.031","journal-title":"Behav Brain Res"},{"key":"6690_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","volume":"286","author":"LM Bohn","year":"1999","unstructured":"Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495\u20132498. https:\/\/doi.org\/10.1126\/science.286.5449.2495","journal-title":"Science"},{"key":"6690_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/35047086","volume":"408","author":"LM Bohn","year":"2000","unstructured":"Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720\u2013723. https:\/\/doi.org\/10.1038\/35047086","journal-title":"Nature"},{"key":"6690_CR5","doi-asserted-by":"publisher","first-page":"10265","DOI":"10.1523\/JNEUROSCI.23-32-10265.2003","volume":"23","author":"LM Bohn","year":"2003","unstructured":"Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, Dykstra LA, Caron MG (2003) Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23:10265\u201310273. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-32-10265.2003","journal-title":"J Neurosci"},{"key":"6690_CR6","doi-asserted-by":"publisher","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","volume":"9","author":"TF Brust","year":"2016","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL et al (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9:ra117. https:\/\/doi.org\/10.1126\/scisignal.aai8441","journal-title":"Sci Signal"},{"key":"6690_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.tips.2017.08.004","volume":"38","author":"HCS Chan","year":"2017","unstructured":"Chan HCS, McCarthy D, Li J, Palczewski K, Yuan S (2017) Designing safer analgesics via mu-opioid receptor pathways. Trends Pharmacol Sci 38:1016\u20131037. https:\/\/doi.org\/10.1016\/j.tips.2017.08.004","journal-title":"Trends Pharmacol Sci"},{"key":"6690_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000634","author":"JC Cornelissen","year":"2021","unstructured":"Cornelissen JC, Blough BE, Bohn LM, Negus SS, Banks ML (2021) Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys. Behav Pharmacol. https:\/\/doi.org\/10.1097\/FBP.0000000000000634","journal-title":"Behav Pharmacol"},{"key":"6690_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.112.201616","volume":"344","author":"SM DeWire","year":"2013","unstructured":"DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM et al (2013) A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708\u2013717. https:\/\/doi.org\/10.1124\/jpet.112.201616","journal-title":"J Pharmacol Exp Ther"},{"key":"6690_CR10","doi-asserted-by":"publisher","first-page":"e4943","DOI":"10.1097\/MD.0000000000004943","volume":"95","author":"Z Ding","year":"2016","unstructured":"Ding Z, Wang K, Wang B, Zhou N, Li H, Yan B (2016) Efficacy and tolerability of oxycodone versus fentanyl for intravenous patient-controlled analgesia after gastrointestinal laparotomy: a prospective, randomized, double-blind study. Medicine (Baltimore) 95:e4943. https:\/\/doi.org\/10.1097\/MD.0000000000004943","journal-title":"Medicine (Baltimore)"},{"key":"6690_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.bja.2020.06.057","volume":"125","author":"H Ding","year":"2020","unstructured":"Ding H, Kiguchi N, Perrey DA, Nguyen T, Czoty PW, Hsu FC et al (2020) Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. Br J Anaesth 125:596\u2013604. https:\/\/doi.org\/10.1016\/j.bja.2020.06.057","journal-title":"Br J Anaesth"},{"key":"6690_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaz3140","author":"A Gillis","year":"2020","unstructured":"Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C et al (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aaz3140","journal-title":"Sci Signal"},{"key":"6690_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41386-019-0491-8","volume":"45","author":"TW Grim","year":"2020","unstructured":"Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho JH, Acevedo-Canabal A et al (2020) A G protein signaling-biased agonist at the \u03bc-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology 45:416\u2013425. https:\/\/doi.org\/10.1038\/s41386-019-0491-8","journal-title":"Neuropsychopharmacology"},{"key":"6690_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.anclin.2018.09.010","volume":"37","author":"JL Gross","year":"2019","unstructured":"Gross JL, Pareta AR, Elkassabany NM (2019) Pain management in trauma in the age of the opioid crisis. Anesthesiol Clin 37:79\u201391. https:\/\/doi.org\/10.1016\/j.anclin.2018.09.010","journal-title":"Anesthesiol Clin"},{"key":"6690_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0165-6147(03)00167-6","volume":"24","author":"T Kenakin","year":"2003","unstructured":"Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346\u2013354. https:\/\/doi.org\/10.1016\/S0165-6147(03)00167-6","journal-title":"Trends Pharmacol Sci"},{"key":"6690_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0165-6147(98)01279-6","volume":"20","author":"BL Kieffer","year":"1999","unstructured":"Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19\u201326. https:\/\/doi.org\/10.1016\/s0165-6147(98)01279-6","journal-title":"Trends Pharmacol Sci"},{"key":"6690_CR17","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1111\/bph.14805","volume":"176","author":"L Kudla","year":"2019","unstructured":"Kudla L, Bugno R, Skupio U, Wiktorowska L, Solecki W, Wojtas A, Golembiowska K et al (2019) Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine. Br J Pharmacol 176:4434\u20134445. https:\/\/doi.org\/10.1111\/bph.14805","journal-title":"Br J Pharmacol"},{"key":"6690_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/pharmaceutics14010055","volume":"14","author":"L Kudla","year":"2021","unstructured":"Kudla L, Bugno R, Podlewska S, Szumiec L, Wiktorowska L, Bojarski AJ, Przewlocki R (2021) Comparison of an addictive potential of \u03bc-opioid receptor agonists with G Protein bias: behavioral and molecular modeling studies. Pharmaceutics 14:55. https:\/\/doi.org\/10.3390\/pharmaceutics14010055","journal-title":"Pharmaceutics"},{"key":"6690_CR19","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00213-016-4368-9","volume":"233","author":"RT Lacy","year":"2016","unstructured":"Lacy RT, Strickland JC, Feinstein MA, Robinson AM, Smith MA (2016) The effects of sex, estrous cycle, and social contract on cocaine and heroin self-administration in rats. Psychopharmacology 233:2301\u20132310. https:\/\/doi.org\/10.1007\/s00213-016-4368-9","journal-title":"Psychopharmacology"},{"key":"6690_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/FBP.0000000000000378","volume":"29","author":"LP Legakis","year":"2018","unstructured":"Legakis LP, Bigbee JW, Negus SS (2018) Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity. Behav Pharmacol 29:290\u2013298. https:\/\/doi.org\/10.1097\/FBP.0000000000000378","journal-title":"Behav Pharmacol"},{"key":"6690_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature19112","volume":"537","author":"A Manglik","year":"2016","unstructured":"Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G et al (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185\u2013190. https:\/\/doi.org\/10.1038\/nature19112","journal-title":"Nature"},{"key":"6690_CR22","doi-asserted-by":"publisher","unstructured":"National Research Council (2011) Guide for the care and use of laboratory animals, 8th edn. The National Academies Press, Washington. https:\/\/doi.org\/10.17226\/12910","DOI":"10.17226\/12910"},{"key":"6690_CR23","doi-asserted-by":"publisher","first-page":"108439","DOI":"10.1016\/j.neuropharm.2020.108439","volume":"185","author":"F Pantouli","year":"2021","unstructured":"Pantouli F, Grim TW, Schmid CL, Acevedo-Canabal A, Kennedy NM, Cameron MD et al (2021) Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain. Neuropharmacology 185:108439. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108439","journal-title":"Neuropharmacology"},{"key":"6690_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.pbb.2010.02.009","volume":"95","author":"D Pascual","year":"2010","unstructured":"Pascual D, Goicoechea C, Burgos E, Martin MI (2010) Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. Pharmacol Biochem Behav 95:331\u2013337. https:\/\/doi.org\/10.1016\/j.pbb.2010.02.009","journal-title":"Pharmacol Biochem Behav"},{"key":"6690_CR25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1124\/pr.112.007138","volume":"65","author":"GW Pasternak","year":"2013","unstructured":"Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65:1257\u20131317. https:\/\/doi.org\/10.1124\/pr.112.007138","journal-title":"Pharmacol Rev"},{"key":"6690_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/17460441","volume":"13","author":"JV Pergolizzi","year":"2018","unstructured":"Pergolizzi JV, LeQuang JA, Taylor R, Ossipov MH, Colucci D, Raffa RB (2018) Designing safer analgesics: a focus on mu-opioid receptor pathways. Expert Opin Drug Discov 13:965\u2013972. https:\/\/doi.org\/10.1080\/17460441","journal-title":"Expert Opin Drug Discov"},{"key":"6690_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","volume":"26","author":"Z Rankovic","year":"2016","unstructured":"Rankovic Z, Brust TF, Bohn LM (2016) Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorg Med Chem Lett 26:241\u2013250. https:\/\/doi.org\/10.1016\/j.bmcl.2015.12.024","journal-title":"Bioorg Med Chem Lett"},{"key":"6690_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1124\/mol.112.078659","volume":"82","author":"G Rivero","year":"2012","unstructured":"Rivero G, Llorente J, McPherson J, Cooke A, Mundell SJ, McArdle CA et al (2012) Endomorphin-2: a biased agonist at the mu-opioid receptor. Mol Pharmacol 82:178\u2013188. https:\/\/doi.org\/10.1124\/mol.112.078659","journal-title":"Mol Pharmacol"},{"key":"6690_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0376-8716(98)00067-2","volume":"51","author":"BL Roth","year":"1998","unstructured":"Roth BL, Willins DL, Kroeze WK (1998) G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Drug Alcohol Depend 51:73\u201385. https:\/\/doi.org\/10.1016\/s0376-8716(98)00067-2","journal-title":"Drug Alcohol Depend"},{"issue":"1165\u20131175","key":"6690_CR30","doi-asserted-by":"publisher","first-page":"e1113","DOI":"10.1016\/j.cell.2017.10.035","volume":"171","author":"CL Schmid","year":"2017","unstructured":"Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J et al (2017) Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 171(1165\u20131175):e1113. https:\/\/doi.org\/10.1016\/j.cell.2017.10.035","journal-title":"Cell"},{"key":"6690_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2019.01.020","volume":"150","author":"KL Schweinteck","year":"2019","unstructured":"Schweinteck KL, Faunce KE, Rice KC, Obeng S, Zhang Y, Blough BE et al (2019) Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. Neuropharmacology 150:200\u2013209. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.01.020","journal-title":"Neuropharmacology"},{"key":"6690_CR32","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/bph.15409","volume":"178","author":"S Singleton","year":"2021","unstructured":"Singleton S, Baptista-Hon DT, Edelsten E, McCaughey KS, Camplisson E, Hales TG (2021) TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available \u03bc-opioid receptor number. Br J Pharmacol 178:1855\u20131868. https:\/\/doi.org\/10.1111\/bph.15409","journal-title":"Br J Pharmacol"},{"key":"6690_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coph.2016.11.007","volume":"32","author":"ER Siuda","year":"2017","unstructured":"Siuda ER, Carr R, Rominger DH, Violin JD (2017) Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol 32:77\u201384. https:\/\/doi.org\/10.1016\/j.coph.2016.11.007","journal-title":"Curr Opin Pharmacol"},{"key":"6690_CR34","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","volume":"155","author":"DG Soergel","year":"2014","unstructured":"Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM et al (2014) Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155:1829\u20131835. https:\/\/doi.org\/10.1016\/j.pain.2014.06.011","journal-title":"Pain"},{"key":"6690_CR35","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1021\/acs.biochem.1c00466","volume":"61","author":"EL Stahl","year":"2022","unstructured":"Stahl EL, Bohn LB (2022) Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists. Biochemistry 61:1923\u20131935. https:\/\/doi.org\/10.1021\/acs.biochem.1c00466","journal-title":"Biochemistry"},{"key":"6690_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0304-3959(94)90130-9","volume":"58","author":"KJ Sufka","year":"1994","unstructured":"Sufka KJ (1994) Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain. Pain 58:355\u2013366. https:\/\/doi.org\/10.1016\/0304-3959(94)90130-9","journal-title":"Pain"},{"key":"6690_CR37","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1523\/JNEUROSCI.2077-05.2005","volume":"25","author":"M Thomsen","year":"2005","unstructured":"Thomsen M, Woldbye DP, Wortwein G, Fink-Jensen A, Wess J, Caine SB (2005) Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mic. J Neurosci 25:8141\u20138149. https:\/\/doi.org\/10.1523\/JNEUROSCI.2077-05.2005","journal-title":"J Neurosci"},{"key":"6690_CR38","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","volume":"234","author":"EA Townsend","year":"2017","unstructured":"Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB (2017) Effects of Nalfurafine on the reinforcing, thermal, antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology (Berl) 234:2597\u20132605. https:\/\/doi.org\/10.1007\/s00213-017-4652-3","journal-title":"Psychopharmacology (Berl)"},{"key":"6690_CR39","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","volume":"59","author":"A Varadi","year":"2016","unstructured":"Varadi A, Marrone GF, Palmer TC, Narayan A, Szabo MR, Le Rouzic V et al (2016) Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2. J Med Chem 59:8381\u20138397. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00748","journal-title":"J Med Chem"},{"key":"6690_CR40","doi-asserted-by":"publisher","first-page":"R300","DOI":"10.1152\/ajpregu.00022.2006","volume":"291","author":"X Wang","year":"2006","unstructured":"Wang X, Traub RJ, Murphy AZ (2006) Persistent pain model reveals sex difference in morphine potency. Am J Physiol Regul Integr Comp Physiol 291:R300\u2013R306. https:\/\/doi.org\/10.1152\/ajpregu.00022.2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"6690_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","volume":"192","author":"CA Zamarripa","year":"2018","unstructured":"Zamarripa CA, Edwards SR, Qureshi HN, Yi JN, Blough BE, Freeman KB (2018) The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend 192:158\u2013162. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.002","journal-title":"Drug Alcohol Depend"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06690-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06690-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06690-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T06:04:15Z","timestamp":1731737055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06690-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6690"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06690-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}